AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients
NCT00180115
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
400
Enrollment
OTHER
Sponsor class
Conditions
Leukemia, Nonlymphoblastic, Acute
Interventions
DRUG:
Cytarabine Dosage
Sponsor
Technische Universität Dresden